Clinical Trial: Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab Induction Therapy on Allo-HSCT in Adults With Ph- B-ALL

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930105) titled 'Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab Induction Therapy on Allo-HSCT in Adults With Ph- B-ALL' on April 08.

Brief Summary: This single-arm, prospective, multicenter, phase II study will enroll newly diagnosed Philadelphia chromosome-negative (Ph-) acute B-cell lymphoblastic leukemia (B-ALL) patients aged 18-60 years. Participants will receive sequential low-intensity chemotherapy followed by a two-week blinatumomab induction therapy. Patients achieving morphological complete remission (CR) will undergo two cycles of consolidation chemotherapy. Those with minimal residual disease (MRD)-negative...